# US 2003/0166666 A1 · Diimino-piperazine derivatives for use as modulators of cell regulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0166666 A1
- Document ID: US20030166666A1
- Status: Published application
- Kind: A1
- Application number: 10/357,297
- Filed: 2003-02-03
- Published: 2003-09-04
- Earliest claimed: 1999-11-24
- Assignees: Emory University
- Inventors: Alfred H. Merrill JR.; Lisa Warden; Dennis C. Liotta
- Web page: https://patentgrep.com/patent/US20030166666A1

## CPC

- C07D 241/06: having one or two double bonds between ring members or between ring members and non-ring members
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions, methods of use, isolation and biosynthesis of diimino-piperazine derivatives useful for the modification of sphingolipid metabolism and other biological functions are described. The preferred derivative is 2,6-bis-(ω-aminobutyl)-3,5-diimino-piperazine. This is a naturally occurring biochemical compound isolated from cells. The diimino-piperazine derivatives are useful as therapeutic agents when administered to patients to treat diseases and disorders involving cell regulation.

## Claims

### Claim 1

A diimino-piperazine composition comprising a cationic diimino-piperazine compound that inhibits sphingolipid metabolism, wherein the compound has a molecular weight less than 3000 daltons.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the compound inhibits sphingosine burst.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the compound has a molecular weight between approximately 130 and 240 daltons.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the compound has the following structural formula:
11
wherein
R is independently H, alkyl, aryl, heteroaryl, —C(O)R, —C(NR)OR, —C(O)NR2, —C(NR)NR2, —C(NR)SR or —C(S)NR2;
R1, R2, R3 and R4 are independently H, R, (CH2)nOR, (CH2)nNR2, CH2O(CH2)nOR, or CH2O(CH2)nNR2
where n=1 to 6; and
X and Y are independently O, NR1, S or CR12.

### Claim 5 (depends on 1)

The composition of claim 1 wherein the compound has the following structural formula:
12
wherein
R is independently H, alkyl, aryl, heteroaryl, —C(O)R, —C(NR)OR, —C(O)NR2, —C(NR)NR2, —C(NR)SR or —C(S)NR2;
R1, R2, R3 and R4 are independently H, R, (CH2)nOR, (CH2)nNR2, CH2O(CH2)nOR, or CH2O(CH2)nNR2
where n=1 to 6;
X is independently O, NR1, S or CR12; and
Z is independently OR1, NR12, SR1.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the compound has the following structural formula:
13
wherein
R is independently H, alkyl, aryl, heteroaryl, —C(O)R, —C(NR)OR, —C(O)NR2, —C(NR)NR2, —C(NR)SR or —C(S)NR2;
R1, R2, R3 and R4 are independently H, R, (CH2)nOR, (CH2)nNR2, CH2O(CH2)nOR, or CH2O(CH2)nNR2
where n=1 to 6;
X is independently O, NR1, S or CR12; and
Z is independently O, NR1 or S.

### Claim 7 (depends on 1)

The composition of claim 1 wherein the compound has the following structural formula:
14
wherein
R is independently H, alkyl, aryl, heteroaryl, —C(O)R, —C(NR)OR, —C(O)NR2, —C(NR)NR2, —C(NR)SR or —C(S)NR2;
R1, R2, R3 and R4 are independently H, R, (CH2)nOR, (CH2)nNR2, CH2O(CH2)nOR, or CH2O(CH2)nNR2
where n=1 to 6;
W is independently OR1, NR12, SR1, (CH2)nOR1, (CH2)nSR1 or (CH2)nNR12
where n=1 to 6;
Z is independently OR1, NR12, SR1.

### Claim 8 (depends on 1)

The composition of claim 1 wherein the compound has the following structural formula:
15

### Claim 9 (depends on 1)

The composition of claim 1 wherein the compound is 2,6-bis-(ω-aminobutyl)-3,5-diimino-piperazine.

### Claim 10 (depends on 1)

The composition of claim 1 wherein the compound is isolated from a biological sample.

### Claim 11 (depends on 1)

The composition of claim 1 wherein the compound is synthetic.

### Claim 12

A method for synthesizing a diimino-piperazine compound comprising:
a. cyclizing bis-nitrile;
b. replacing amino hydrogens of the cyclized bis-nitrile with a protecting group to produce an intermediate;
c. alkylating the intermediate; and
d. deprotecting the alkylated intermediate to form the diimino-piperidine compound.

### Claim 13

A method for treating a cell signaling pathway disease or disorder comprising administering to a patient having the disease or disorder a diimino-piperazine composition comprising a cationic diimino-piperazine compound that inhibits sphingolipid metabolism, wherein the compound has a molecular weight less than 3000 daltons.

### Claim 14 (depends on 13)

The method of claim 13 wherein the compound has the following structural formula:
16
wherein
R is independently H, alkyl, aryl, heteroaryl, —C(O)R, —C(NR)OR, —C(O)NR2, —C(NR)NR2, —C(NR)SR or —C(S)NR2;
R1, R2, R3 and R4 are independently H, R, (CH2)nOR, (CH2)nNR2, CH2O(CH2)nOR, or CH2O(CH2)nNR2
where n=1 to 6; and
X and Y are independently O, NR1, S or CR12.

### Claim 15 (depends on 13)

The method of claim 13 wherein the compound has the following structural formula:
17
wherein
R is independently H, alkyl, aryl, heteroaryl, —C(O)R, —C(NR)OR, —C(O)NR2, —C(NR)NR2, —C(NR)SR or —C(S)NR2;
R1, R2, R3 and R4 are independently H, R, (CH2)nOR, (CH2)nNR2, CH2O(CH2)nOR, or CH2O(CH2)nNR2
where n=1 to 6;
X is independently O, NR1, S or CR12; and
Z is independently OR1, NR12, SR1.

### Claim 16 (depends on 13)

The method of claim 13 wherein the compound has the following structural formula:
18
wherein
R is independently H, alkyl, aryl, heteroaryl, —C(O)R, —C(NR)OR, —C(O)NR2, —C(NR)NR2, —C(NR)SR or —C(S)NR2;
R1, R2, R3 and R4 are independently H, R, (CH2)nOR, (CH2)nNR2, CH2O(CH2)nOR, or CH2O(CH2)nNR2
where n=1 to 6;
X is independently O, NR1, S or CR12; and
Z is independently O, NR1 or S.

### Claim 17 (depends on 13)

The method of claim 13 wherein the compound has the following structural formula:
19
wherein
R is independently H, alkyl, aryl, heteroaryl, —C(O)R, —C(NR)OR, —C(O)NR2, —C(NR)NR2, —C(NR)SR or —C(S)NR2;
R1, R2, R3 and R4 are independently H, R, (CH2)nOR, (CH2)nNR2, CH2O(CH2)nOR, or CH2O(CH2)nNR2
where n=1 to 6;
W is independently OR1, NR12, SR1, (CH2)nOR1, (CH2)nSR1 or (CH2)nNR12
where n=1 to 6;
Z is independently OR1, NR12, SR1.

### Claim 18 (depends on 13)

The method of claim 13 wherein the compound has the following structural formula:
20

### Claim 19 (depends on 13)

The method of claim 13 wherein the compound is 2,6-bis-(ω-aminobutyl)-3,5-diimino-piperazine.

### Claim 20 (depends on 13)

The method of claim 13 wherein the cell signaling pathway disease or disorder is selected from the group consisting of cancer, heart attack, stroke, and inflammatory disease.
